Loratadine
- Generic Name
- Loratadine
- Brand Names
- Alavert, Alavert D, Allerclear, Claritin, Claritin-D, Diphen, Loradamed, Wal-itin, Wal-itin D
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN2O2
- CAS Number
- 79794-75-5
- Unique Ingredient Identifier
- 7AJO3BO7QN
- Background
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
- Indication
Loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.
- Associated Conditions
- Allergic Dermatologic Disorders, Allergic Reaction, Allergic Rhinitis (AR), Allergy to Tree Pollen, Chronic Urticaria, Common Cold, Epiphora, Eye pruritus, Fever, Nasal Congestion, Nasal Itching, Pain, Perennial Allergic Rhinitis (PAR), Pruritus, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Sensation of burning in the eyes, Watery itchy eyes
Benjakul Extract and Loratadine for Treatment Allergic Rhinitis Patients
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Thammasat University
- Target Recruit Count
- 60
- Registration Number
- NCT03376594
- Locations
- 🇹🇭
Faculty of Medicine, Khlong Luang, Pathumthani, Thailand
A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT03196531
- Locations
- 🇨🇳
Xiangya Hospital Central South University, ChangSha, China
A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03151720
- Locations
- 🇨🇳
Tri-Service Genaral Hospital, Taipei, Taiwan
Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
- Conditions
- SARAllergic RhinitisRhinitis, Allergic, SeasonalHay Fever
- Interventions
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2017-04-20
- Target Recruit Count
- 683
- Registration Number
- NCT02932774
Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Qufeng Shengshi Fang and Loratadine
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT02653339
- Locations
- 🇨🇳
Peking Union Medical College Hospital traditional Chinese medicine department, Beijing, Beijing, China
To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup
- Conditions
- Histamine H1 Antagonists, Non-Sedating
- Interventions
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT02593747
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 24
- Registration Number
- NCT02583594
- Locations
- 🇪🇸
Investigational Site Number 724001, Barcelona, Spain
Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Thai Traditional Medical Knowledge Fund
- Target Recruit Count
- 80
- Registration Number
- NCT02576808
- Locations
- 🇹🇭
Thammasat University Hospital, Khlong Luang,, Pathumthani, Thailand
Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Universidade do Sul de Santa Catarina
- Target Recruit Count
- 73
- Registration Number
- NCT02513290
Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
- Conditions
- Kidney Transplant
- Interventions
- Biological: InfliximabBiological: Thymoglobulin®Biological: Placebo for Infliximab
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2022-08-16
- Target Recruit Count
- 290
- Registration Number
- NCT02495077
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.